138 related articles for article (PubMed ID: 16507393)
1. Current directions for COX-2 inhibition in breast cancer.
Chow LW; Loo WT; Toi M
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S281-4. PubMed ID: 16507393
[TBL] [Abstract][Full Text] [Related]
2. Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial.
Chow LW; Yip AY; Chu WP; Loo WT; Toi M
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):112-9. PubMed ID: 21236344
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed.
Liu R; Xu KP; Tan GS
Eur J Pharmacol; 2015 Dec; 769():127-33. PubMed ID: 26548623
[TBL] [Abstract][Full Text] [Related]
4. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.
Martin LA; Davies GL; Weigel MT; Betambeau N; Hills MJ; Salter J; Walsh G; A'Hern R; Dowsett M
Breast Cancer Res Treat; 2010 Oct; 123(3):829-36. PubMed ID: 20697803
[TBL] [Abstract][Full Text] [Related]
5. Serum lipid profiles in patients receiving endocrine treatment for breast cancer--the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial.
Chow LW; Cheng CW; Wong JL; Toi M
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S302-5. PubMed ID: 16507398
[TBL] [Abstract][Full Text] [Related]
6. Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Tury S; Becette V; Assayag F; Vacher S; Benoist C; Kamal M; Marangoni E; Bièche I; Lerebours F; Callens C
Oncotarget; 2016 Dec; 7(51):85124-85141. PubMed ID: 27835884
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer.
Chow LW; Yip AY; Loo WT; Lam CK; Toi M
J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):13-7. PubMed ID: 18514508
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib induced apoptosis against different breast cancer cell lines by down-regulated NF-κB pathway.
Wang G; Li J; Zhang L; Huang S; Zhao X; Zhao X
Biochem Biophys Res Commun; 2017 Aug; 490(3):969-976. PubMed ID: 28666869
[TBL] [Abstract][Full Text] [Related]
9. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Generali D; Buffa FM; Deb S; Cummings M; Reid LE; Taylor M; Andreis D; Allevi G; Ferrero G; Byrne D; Martinotti M; Bottini A; Harris AL; Lakhani SR; Fox SB
Br J Cancer; 2014 Jul; 111(1):46-54. PubMed ID: 24874483
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment of breast cancer cell lines with vitamin D and COX-2 inhibitors.
Thill M; Reichert K; Woeste A; Polack S; Fischer D; Hoellen F; Rody A; Friedrich M; Köster F
Anticancer Res; 2015 Feb; 35(2):1189-95. PubMed ID: 25667510
[TBL] [Abstract][Full Text] [Related]
11. Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Chow LW; Loo WT; Wai CC; Lui EL; Zhu L; Toi M
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S298-301. PubMed ID: 16507397
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Ohtsu N; Takaoka K; Segawa E; Hashitani S; Noguchi K; Kishimoto H; Urade M
Oncol Rep; 2010 Jul; 24(1):31-6. PubMed ID: 20514441
[TBL] [Abstract][Full Text] [Related]
13. The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function.
Yan YX; Li WZ; Huang YQ; Liao WX
Prostaglandins Other Lipid Mediat; 2012 Jan; 97(1-2):29-35. PubMed ID: 21835258
[TBL] [Abstract][Full Text] [Related]
14. Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer.
Alqahtani AM; Chidambaram K; Pino-Figueroa A; Chandrasekaran B; Dhanaraj P; Venkatesan K
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1916-1927. PubMed ID: 33660801
[TBL] [Abstract][Full Text] [Related]
15. Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy.
Schönthal AH
Anticancer Agents Med Chem; 2010 Jul; 10(6):450-61. PubMed ID: 20879982
[TBL] [Abstract][Full Text] [Related]
16. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.
Lev-Ari S; Zinger H; Kazanov D; Yona D; Ben-Yosef R; Starr A; Figer A; Arber N
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S276-80. PubMed ID: 16507392
[TBL] [Abstract][Full Text] [Related]
17. Reduced expression of cyclooxygenase-2 in primary breast cancer.
Boneberg EM; Legler DF; Senn HJ; Fürstenberger G
J Natl Cancer Inst; 2008 Jul; 100(14):1042-3. PubMed ID: 18612134
[No Abstract] [Full Text] [Related]
18. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2.
Xu HB; Shen FM; Lv QZ
Eur J Pharmacol; 2015 Dec; 769():1-7. PubMed ID: 26407653
[TBL] [Abstract][Full Text] [Related]
20. The potential role of cyclooxygenase-2 (COX-2) during early breast cancer therapy.
Filipovic A; Giamas G; Stebbing J
Ann Oncol; 2011 Aug; 22(8):1700-2. PubMed ID: 21551001
[No Abstract] [Full Text] [Related]
[Next] [New Search]
